人巨细胞病毒部分抗原决定簇基因的克隆、表达及初步应用
|
摘要
人巨细胞病毒(Human Cytomegalovirus，HCMV)为疱疹病毒科β属的双螺旋DNA病毒，在世界范围内分布。HCMV不仅是人类先天性病毒感染的主要病原，而且是免疫功能低下人群(艾滋病患者、器官移植者、免疫抑制治疗者等)并发感染死亡的常见原因之一。由于HCMV感染者通常无症状或无特异性症状，建立HCMV快速、敏感、特异的实验室检测方法并采取早期治疗措施对优生、优育及阻止HCMV的传播具有重要意义。
HCMV感染的检测方法包括病毒分离培养、核酸测定、抗原检测和血清学检测等，每种方法各有优缺点。HCMV原发感染的检测，主要采用血清学方法。HCMVIgM是机体受病毒抗原刺激后最早产生的抗体，是活动性HCMV感染的重要指标之一，因而是检测HCMV感染的常用指标。
目前国内存在大量检测血清HCMV IgM的试剂盒，多使用从HCMV感染的人胚肺二倍体细胞中粗提取的完整病毒抗原，各种检测方法对相同血清的检测结果有很大差别，即是符合率较差。其主要原因为：1．病毒抗原的制备及纯化方法各不相同；2．提取物中含有多种抗原成分，很难进行标准化：3．制备抗原所需的HCMV要在人胚肺细胞中培养，此细胞的蛋白可能对制备的抗原产生污染；4．疱疹病毒有共同抗原，完整的HCMV抗原可以与其它非HCMV病毒感染产生的抗体发生交叉反应。
由于病毒来源的抗原存在敏感性、特异性、标准化等问题，将通过基因工程方法获得的表达产物作为检测用抗原已引起各国学者重视。国内外研究工作者对人巨细胸病毒的一些抗原决定簇进行了免疫原性和特异性研究，期待能够应用于人巨细胞病毒感染的早期诊断。其中gp52(UL44)、pp150(ppUL32)、pp65(ppUL83)、ppUL80a均为强免疫原性蛋白且具有保守的DNA序列，能够特异性识别HCMV IgM抗体。
因此，本研究选择HCMV gp52(UL44)、pp150(ppUL32)、pp65(ppUL83)、ppUL80a抗原性好、特异性强的部分基因片段作为目的基因，应用基因工程技术，得到高效表达的目的工程菌，并对表达产物进行了抗原性研究。
此次研究从HCMV感染的细胞上清液中提取HCMV基因组，本试验用PCR方法从基因组中扩增获得pp150 aa595-614(A)、pp150 aa1006-1042(B)、gp52aa202-434(C)、pp65 aa297-510(D)、ppUL80a aa117-373(E)氨基酸之间的多肽片段的编码基因，用重组PCR的方法将前三个片段重组为新的DNA片段(F)，将D、E、F片段分别克隆至pMD-18T载体测序，核苷酸序列分析证明了PCR扩增目的序列的正确性。测序正确的片段克隆至原核表达载体pGEx-4T-1。构建重组质粒，转化大肠杆菌BL21，经IPTG诱导后成功表达了上述三种蛋白，分别命名为GST-ppUL83、GST-ppUL80a、GST-LINK。通过Western blotting检测其免疫特性，结果显示三种蛋白均能被羊抗人巨细胞病毒多克隆抗体及HOMV IgM阳性血清特异性识别，而载体蛋白与多克隆抗体及阳性血清并不能发生反应，证明这三种蛋白具有良好的抗原特异性，可期待应用于人巨细胞病毒感染的诊断。经蛋白电泳分析表达产物主要以包涵体的形式存在，根据这三种蛋白不同的理化特性，采用不同的方法进行蛋白纯化，获得了较好的纯化效果。
时间分辨荧光免疫分析(Time-resolred fluoroimmunoassay，TRFIA)是上世纪八十年代兴起的一种新型非放射性标记技术，TRFIA巧妙利用镧系元素的荧光特点，克服了普通荧光检测中背景荧光强度大、干扰强的缺点，使强特异性荧光和背景荧光分辨开，几乎可以完全消除背景荧光的干扰，提高了检测的灵敏度。与现在广泛使用的放射免疫分析(RIA)、酶免疫分析(EIA)、化学发光免疫分析(CLIA)、电化学发光免疫分析(ECLIA)相比，具有灵敏度高、操作简便、示踪物稳定、标准曲线范围宽、不受样品自然荧光干扰、无放射性污染、对标记物分子生物活性影响小、多标记等优点，现已成为生物学研究和临床超微量生化检验中一项颇有发展前景的分析手段。
为分析本实验所表达纯化的三种目的蛋白与HCMV IgM的反应能力，将目的蛋白及Microbix Biosystems公司的完整病毒裂解抗原CMV grade2 antigen，运用捕获法TRFIA检测已知HCMV IgM阳性及阴性的血清，两种反应结果进行直线相关分析。分析结果显示，三种目的蛋白单独应用检测血清的结果与完整裂解抗原的检测结果呈正相关，但效果不甚理想(r_s分别为0.947，0.879，0.957)。将三种目的蛋白联合应用检测血清的结果与完整裂解抗原的结果具有良好的相关性，r_s=0.989，P＜0.001，效果明显好于融合蛋白单独应用。其主要原因是虽然本实验所选择gp52、pp150、pp65、ppUL80a均为强免疫原性蛋白且具有保守的DNA序列，对HCMV IgM抗体具有一定的敏感性和特异性，但其可能只与HCMV感染的不同阶段机体产生的特异性IgM发生反应。将三者联合应用，检测效果与完整病毒裂解抗原的检测效果呈良好的正相关关系，说明目的蛋白联合应用与完整裂解抗原之间的相关关系更加密切，在检测血清HCMV IgM方面能更好地代表完整裂解抗原的作用。将三种目的蛋白按最佳比例应用检测100份随机血清，其结果与国内外有代表性的试剂盒检测结果进行比较，计算吻合度测量系数(κ)，吻合程度较高(国外κ=0.905，国内κ=0.701)。
Human cytomegalovirus (HCMV) ,a beta herpesvirus,which has duplex DNA structure ,is ubiquitously distributed in human populations.Although rarely pathogenic in immunocompetent individuals,the virus poses a significant cause of morbidity and mortality in organ allograft ,AIDS patients, immunosuppression patients and so on.Pregnant women are also a risk group for this virus as HCMV is the most common cause of congenital infection.Sience the infections with HCMV either are asymptomatic or are accompanied by symptoms not specific for HCMV(such as fever and leucopenia),laboratory techniques are the sole means of diagnosing HCMV infection. So it has significant sense to build up a fast, sensitive and specific laboratory method for the diagnosis of HCMV, then doctors can take therapeutic measures in the early period of the infection which have positive meaning in aristogenesis and preventing the virus's conveying.
Diagnosis of HCMV infection can be obtained by direct demonstration of the virus or virus components in pathological materials or indirectly through serology. The most direct methods include culture of the virus or detection of viral components ,like viral DNA,RNA and antigens in body fluids or tissue biopsy specimens.Diagnosis of primary HCMV infection is exclusively accomplished by serological methods.Serologic assays are widely used for donor selection and to support the diagnosis of HCMV in the host and to determine whether it is an active or latent infection.Although it indirectly reflects viral activity ,serology provides a cheap alternative method that can readily be automated for routine use.HCMV-specific immunoglobulin M(IgM) is a sensitive and specific indicator of primary HCMV infection in immunocompetent subjects,while it is very often produced during viral reactivation in transplant recipients, ,AIDS patients and so on.
In current serologic assays complex viral lysates are commonly used.However, detection of HCMV-specific IgMvaries widely,and poor agreement has been found among the results obtained with different commercially available kits.The use of these viral lysates has disadvantages because they consist of many viral antigens whose exact compositions are difficult to standardize.Preparation of lysates requires culture of HCMV in fibroblasts,resulting in potential contamination with cellular proteins. Since many transplant recipients may temporarily develop autoantibody responses ,a false-positive reactivity may result.Another problem can arise,since herpesviruses share multiple protein homologues,which can give rise to cross-reactivity in assays based on complex viral lysates.
In order to overcome these problems the viral lysate should be replaced by a defined antigen preparation,preferably consisting of a combination of HCMV-specific and immunodominant antigens,in order to achieve the highest sensitivity and specificity.Recombinant proteins from genetic engineering can be used to detect antibodies to the parent protein.Combinations of such defined immunodominant proteins or peptides may ideally be suited as replacements for complex protein-antigen mixtures. Some antigenic determinants were investigated to seek immunogenic and protective for potential diagnosis.gp52(UL44)、pp150 (ppUL32)、pp65 (ppUL83)、ppUL80a are all immunogenic antigen determinants with most conservative DNA sequences,and can recognize the HCMV-IgM in the serum specifically.
In this study,these five antigenic determinant genes(ppl50 aa595-6149 (A) ,ppl50 aa 1006～1042 (B),gp52 aa202～434 (C), pp65 aa297～510 (D) ,ppUL80a aa117～373 (E)) have been amplified successfully from HCMV genome and then the first three fractions were recombinated into a new fraction(F) by Overlap PCR.Then the three fractions(D、E、F)were cloned into a cloning vector,and the DNA sequencing proved that the fractions amplified by PC R are totally correct.The correct gene fragments were cloned into a prokaryotic expression vector to generate fusion proteins named GST- ppUL83, GST- ppUL80a, GST-LINK respectively, which were induced by IPTG and well expressed in E coli.The HCMV immuno-specificity of these three fusion protein weredetected by western-blotting.All three recombination proteins could be specially recognized by HCMV IgM sera,however the vector protein GST could not react with the infected sera,indicating the ideal antigenicity of the three recombination protein and the application of the HCMV diagnosis.
According to the different bio-characteristic,different purification methods were used to acquire purified antigen,and the three antigens had been purified successfully. Time- resolved fluoroimmunoassay(TRF1A) is a kind of new non- radio marked technique rised from 80's last century. It makes use of the special fluorescence characteristic of the lanthanum series and their chelate to mark antigens,antibodies,probes of nucleic acid and so on.After the reaction system(for example:antigen-antibody reaction,hybridization of nucleic acid probes) occures ,determinant the fluorescence intensity of the reaction product by the TRFIA tester. According to the specific value of the outcome fluorescence intensity and the opposing fluorescence intensity, we can decide the concentration of the analyte in the reaction system. The TRF1A dexterously utilize the special fluorescence characteristics of the lanthanum series :first,the decay time of the fluorescence of the lanthanum series' chelate is very long, which is 10~3-10~6 times of traditional fluorescences ;second:The Stokes bias between the excitation light and the emission light can amount to 290 nm, while the common fluorescences' Stokes bias is only 28 nm. Thus it overcomes the weakness of the common fluorescence examination :strong intensity of the background fluorescence and interference, thusdistinguish the strong particularity fluorescence and the background fluorescences .It can almostly remove the interference of the background fluorescence, raising the sensitivity of the examination. Compared with the common emanation such as radioimmunoassay(RIA),enzyme-immunoassay(EIA),chemiluminescence immune assay(CLIA) ,the TRFIA has some advantages ,for example,the high sensitivity,the simple operation process,the stabilization of the tracer, the wide extent of the standard curve,no radioaction contaminate,the little interference in the bioactivity of the marked mass,and so on.Now,TRFIA is one of the excellent analysis methods in biological investigation and clinical ultramicro-examination of biochemistry.
To check whether the three pured purpose proteins contain the antigenic determinant that can react specially with the HCMV lgM in the sera,we make use of the purpose proteins and the complete virus antigen of schizolysis(CMV grade2 antigen of Microbix Biosystems company), utilizing the TRFIA method to detect the serums which we have already known the positive or negative of HCMV IgM, then the results were analyzed by Linear Correlation. The analysis result demonstrat that the result of the three purpose proteins used prospectively has positive correlation with the result of CMV grade2 antigen, but the result is not very well.While the result of the three purpose proteins used together has fine positive correlation with the result of CMV grade2 antigen, r_s=0.989. The main reason may be although the proteins we chosed in this experiment:gp52, pp150, pp65, ppUL80a are all proteins with strong immunogenicity, conservative sequence of DNA and have the ability to react with HCMV IgM sensitivity and specificity, they can only react with HCMV IgM of particular stage of HCMV infection. The analysis of the humoral immune response elicited during natural infection has repeatedly shown that the basic phosphoprotein of 150 KDa encoded by UL32(ppUL32) and localized in the viral tegument is highly immunlgenic and is recognized by sera from nearly 100% of the HCMV-seropositive subjects tested.In this molecule at least two epitopes have been identified and shown to react efficiently with human immunolobulins. In particular, the analysis of several ppUL32 fusion proteins showed that a region localized in the last 43 amino acids at the carboxy terminus of the molecule(amino acids 1006 to 1048)reacts with more than 80% IgM-positive serum samples. When chemically synthesized, antother region localized between anino acids 595 and 614 gave a positive reaction with almost 100%IgG-positive serum samples. When it is expressed as recombinant protein,this region also reacted efficiently with HCMV=specific IgM.The two coding regions were recently fused together and were shown to produce a double-epitope fusion protein which can replace the entire p150 molecule in its lgM-binding ability. Another HCMV protein which reacts very well with IgM is ppUL44, the nonstructural DNA-binding protein of 52 kDa. The carboxy-terminal part of th molecule was chosen because it does not contain relevant amino acid sequences cross-reacting with the homologous protein of other members of the Herpesviridae family. The carboxy-terminal half of this protein was expressed and tested with human sera alone and in combination with the double-ppUL32 epitope fusion protein. Besides ppUL32 and ppUL44, two other HCMV proteins were chosen:the major matrix protein ppUL83 and the assembly protein(ppUL80a). The first is known to induce a strong IgM response, and antibodies reacting exclusively to this protein were described during primary infection. The second protein was included in the study because in HCMV-seropositive transplant recipients undergoing viral reactivation, IgM to this protein is very often the first marker to be detected. Use the three proteins together to detect the serums which we have already known the positive or negative of HCMV IgM, the result has fine positive correlation with the result of CMV grade2 antigen,which demonstrate that the chosen proteins contains the antigenic determinants that can react sensitively and specifically with the HCMV IgM. Use the three proteins together according to the optimum to check 100 random sera, this result compared with the results of commercial kits from internal and abroad having excellent efficiency, didn't show significant difference.
HCMV感染的检测方法包括病毒分离培养、核酸测定、抗原检测和血清学检测等，每种方法各有优缺点。HCMV原发感染的检测，主要采用血清学方法。HCMVIgM是机体受病毒抗原刺激后最早产生的抗体，是活动性HCMV感染的重要指标之一，因而是检测HCMV感染的常用指标。
目前国内存在大量检测血清HCMV IgM的试剂盒，多使用从HCMV感染的人胚肺二倍体细胞中粗提取的完整病毒抗原，各种检测方法对相同血清的检测结果有很大差别，即是符合率较差。其主要原因为：1．病毒抗原的制备及纯化方法各不相同；2．提取物中含有多种抗原成分，很难进行标准化：3．制备抗原所需的HCMV要在人胚肺细胞中培养，此细胞的蛋白可能对制备的抗原产生污染；4．疱疹病毒有共同抗原，完整的HCMV抗原可以与其它非HCMV病毒感染产生的抗体发生交叉反应。
由于病毒来源的抗原存在敏感性、特异性、标准化等问题，将通过基因工程方法获得的表达产物作为检测用抗原已引起各国学者重视。国内外研究工作者对人巨细胸病毒的一些抗原决定簇进行了免疫原性和特异性研究，期待能够应用于人巨细胞病毒感染的早期诊断。其中gp52(UL44)、pp150(ppUL32)、pp65(ppUL83)、ppUL80a均为强免疫原性蛋白且具有保守的DNA序列，能够特异性识别HCMV IgM抗体。
因此，本研究选择HCMV gp52(UL44)、pp150(ppUL32)、pp65(ppUL83)、ppUL80a抗原性好、特异性强的部分基因片段作为目的基因，应用基因工程技术，得到高效表达的目的工程菌，并对表达产物进行了抗原性研究。
此次研究从HCMV感染的细胞上清液中提取HCMV基因组，本试验用PCR方法从基因组中扩增获得pp150 aa595-614(A)、pp150 aa1006-1042(B)、gp52aa202-434(C)、pp65 aa297-510(D)、ppUL80a aa117-373(E)氨基酸之间的多肽片段的编码基因，用重组PCR的方法将前三个片段重组为新的DNA片段(F)，将D、E、F片段分别克隆至pMD-18T载体测序，核苷酸序列分析证明了PCR扩增目的序列的正确性。测序正确的片段克隆至原核表达载体pGEx-4T-1。构建重组质粒，转化大肠杆菌BL21，经IPTG诱导后成功表达了上述三种蛋白，分别命名为GST-ppUL83、GST-ppUL80a、GST-LINK。通过Western blotting检测其免疫特性，结果显示三种蛋白均能被羊抗人巨细胞病毒多克隆抗体及HOMV IgM阳性血清特异性识别，而载体蛋白与多克隆抗体及阳性血清并不能发生反应，证明这三种蛋白具有良好的抗原特异性，可期待应用于人巨细胞病毒感染的诊断。经蛋白电泳分析表达产物主要以包涵体的形式存在，根据这三种蛋白不同的理化特性，采用不同的方法进行蛋白纯化，获得了较好的纯化效果。
时间分辨荧光免疫分析(Time-resolred fluoroimmunoassay，TRFIA)是上世纪八十年代兴起的一种新型非放射性标记技术，TRFIA巧妙利用镧系元素的荧光特点，克服了普通荧光检测中背景荧光强度大、干扰强的缺点，使强特异性荧光和背景荧光分辨开，几乎可以完全消除背景荧光的干扰，提高了检测的灵敏度。与现在广泛使用的放射免疫分析(RIA)、酶免疫分析(EIA)、化学发光免疫分析(CLIA)、电化学发光免疫分析(ECLIA)相比，具有灵敏度高、操作简便、示踪物稳定、标准曲线范围宽、不受样品自然荧光干扰、无放射性污染、对标记物分子生物活性影响小、多标记等优点，现已成为生物学研究和临床超微量生化检验中一项颇有发展前景的分析手段。
为分析本实验所表达纯化的三种目的蛋白与HCMV IgM的反应能力，将目的蛋白及Microbix Biosystems公司的完整病毒裂解抗原CMV grade2 antigen，运用捕获法TRFIA检测已知HCMV IgM阳性及阴性的血清，两种反应结果进行直线相关分析。分析结果显示，三种目的蛋白单独应用检测血清的结果与完整裂解抗原的检测结果呈正相关，但效果不甚理想(r_s分别为0.947，0.879，0.957)。将三种目的蛋白联合应用检测血清的结果与完整裂解抗原的结果具有良好的相关性，r_s=0.989，P＜0.001，效果明显好于融合蛋白单独应用。其主要原因是虽然本实验所选择gp52、pp150、pp65、ppUL80a均为强免疫原性蛋白且具有保守的DNA序列，对HCMV IgM抗体具有一定的敏感性和特异性，但其可能只与HCMV感染的不同阶段机体产生的特异性IgM发生反应。将三者联合应用，检测效果与完整病毒裂解抗原的检测效果呈良好的正相关关系，说明目的蛋白联合应用与完整裂解抗原之间的相关关系更加密切，在检测血清HCMV IgM方面能更好地代表完整裂解抗原的作用。将三种目的蛋白按最佳比例应用检测100份随机血清，其结果与国内外有代表性的试剂盒检测结果进行比较，计算吻合度测量系数(κ)，吻合程度较高(国外κ=0.905，国内κ=0.701)。
Human cytomegalovirus (HCMV) ,a beta herpesvirus,which has duplex DNA structure ,is ubiquitously distributed in human populations.Although rarely pathogenic in immunocompetent individuals,the virus poses a significant cause of morbidity and mortality in organ allograft ,AIDS patients, immunosuppression patients and so on.Pregnant women are also a risk group for this virus as HCMV is the most common cause of congenital infection.Sience the infections with HCMV either are asymptomatic or are accompanied by symptoms not specific for HCMV(such as fever and leucopenia),laboratory techniques are the sole means of diagnosing HCMV infection. So it has significant sense to build up a fast, sensitive and specific laboratory method for the diagnosis of HCMV, then doctors can take therapeutic measures in the early period of the infection which have positive meaning in aristogenesis and preventing the virus's conveying.
Diagnosis of HCMV infection can be obtained by direct demonstration of the virus or virus components in pathological materials or indirectly through serology. The most direct methods include culture of the virus or detection of viral components ,like viral DNA,RNA and antigens in body fluids or tissue biopsy specimens.Diagnosis of primary HCMV infection is exclusively accomplished by serological methods.Serologic assays are widely used for donor selection and to support the diagnosis of HCMV in the host and to determine whether it is an active or latent infection.Although it indirectly reflects viral activity ,serology provides a cheap alternative method that can readily be automated for routine use.HCMV-specific immunoglobulin M(IgM) is a sensitive and specific indicator of primary HCMV infection in immunocompetent subjects,while it is very often produced during viral reactivation in transplant recipients, ,AIDS patients and so on.
In current serologic assays complex viral lysates are commonly used.However, detection of HCMV-specific IgMvaries widely,and poor agreement has been found among the results obtained with different commercially available kits.The use of these viral lysates has disadvantages because they consist of many viral antigens whose exact compositions are difficult to standardize.Preparation of lysates requires culture of HCMV in fibroblasts,resulting in potential contamination with cellular proteins. Since many transplant recipients may temporarily develop autoantibody responses ,a false-positive reactivity may result.Another problem can arise,since herpesviruses share multiple protein homologues,which can give rise to cross-reactivity in assays based on complex viral lysates.
In order to overcome these problems the viral lysate should be replaced by a defined antigen preparation,preferably consisting of a combination of HCMV-specific and immunodominant antigens,in order to achieve the highest sensitivity and specificity.Recombinant proteins from genetic engineering can be used to detect antibodies to the parent protein.Combinations of such defined immunodominant proteins or peptides may ideally be suited as replacements for complex protein-antigen mixtures. Some antigenic determinants were investigated to seek immunogenic and protective for potential diagnosis.gp52(UL44)、pp150 (ppUL32)、pp65 (ppUL83)、ppUL80a are all immunogenic antigen determinants with most conservative DNA sequences,and can recognize the HCMV-IgM in the serum specifically.
In this study,these five antigenic determinant genes(ppl50 aa595-6149 (A) ,ppl50 aa 1006～1042 (B),gp52 aa202～434 (C), pp65 aa297～510 (D) ,ppUL80a aa117～373 (E)) have been amplified successfully from HCMV genome and then the first three fractions were recombinated into a new fraction(F) by Overlap PCR.Then the three fractions(D、E、F)were cloned into a cloning vector,and the DNA sequencing proved that the fractions amplified by PC R are totally correct.The correct gene fragments were cloned into a prokaryotic expression vector to generate fusion proteins named GST- ppUL83, GST- ppUL80a, GST-LINK respectively, which were induced by IPTG and well expressed in E coli.The HCMV immuno-specificity of these three fusion protein weredetected by western-blotting.All three recombination proteins could be specially recognized by HCMV IgM sera,however the vector protein GST could not react with the infected sera,indicating the ideal antigenicity of the three recombination protein and the application of the HCMV diagnosis.
According to the different bio-characteristic,different purification methods were used to acquire purified antigen,and the three antigens had been purified successfully. Time- resolved fluoroimmunoassay(TRF1A) is a kind of new non- radio marked technique rised from 80's last century. It makes use of the special fluorescence characteristic of the lanthanum series and their chelate to mark antigens,antibodies,probes of nucleic acid and so on.After the reaction system(for example:antigen-antibody reaction,hybridization of nucleic acid probes) occures ,determinant the fluorescence intensity of the reaction product by the TRFIA tester. According to the specific value of the outcome fluorescence intensity and the opposing fluorescence intensity, we can decide the concentration of the analyte in the reaction system. The TRF1A dexterously utilize the special fluorescence characteristics of the lanthanum series :first,the decay time of the fluorescence of the lanthanum series' chelate is very long, which is 10~3-10~6 times of traditional fluorescences ;second:The Stokes bias between the excitation light and the emission light can amount to 290 nm, while the common fluorescences' Stokes bias is only 28 nm. Thus it overcomes the weakness of the common fluorescence examination :strong intensity of the background fluorescence and interference, thusdistinguish the strong particularity fluorescence and the background fluorescences .It can almostly remove the interference of the background fluorescence, raising the sensitivity of the examination. Compared with the common emanation such as radioimmunoassay(RIA),enzyme-immunoassay(EIA),chemiluminescence immune assay(CLIA) ,the TRFIA has some advantages ,for example,the high sensitivity,the simple operation process,the stabilization of the tracer, the wide extent of the standard curve,no radioaction contaminate,the little interference in the bioactivity of the marked mass,and so on.Now,TRFIA is one of the excellent analysis methods in biological investigation and clinical ultramicro-examination of biochemistry.
To check whether the three pured purpose proteins contain the antigenic determinant that can react specially with the HCMV lgM in the sera,we make use of the purpose proteins and the complete virus antigen of schizolysis(CMV grade2 antigen of Microbix Biosystems company), utilizing the TRFIA method to detect the serums which we have already known the positive or negative of HCMV IgM, then the results were analyzed by Linear Correlation. The analysis result demonstrat that the result of the three purpose proteins used prospectively has positive correlation with the result of CMV grade2 antigen, but the result is not very well.While the result of the three purpose proteins used together has fine positive correlation with the result of CMV grade2 antigen, r_s=0.989. The main reason may be although the proteins we chosed in this experiment:gp52, pp150, pp65, ppUL80a are all proteins with strong immunogenicity, conservative sequence of DNA and have the ability to react with HCMV IgM sensitivity and specificity, they can only react with HCMV IgM of particular stage of HCMV infection. The analysis of the humoral immune response elicited during natural infection has repeatedly shown that the basic phosphoprotein of 150 KDa encoded by UL32(ppUL32) and localized in the viral tegument is highly immunlgenic and is recognized by sera from nearly 100% of the HCMV-seropositive subjects tested.In this molecule at least two epitopes have been identified and shown to react efficiently with human immunolobulins. In particular, the analysis of several ppUL32 fusion proteins showed that a region localized in the last 43 amino acids at the carboxy terminus of the molecule(amino acids 1006 to 1048)reacts with more than 80% IgM-positive serum samples. When chemically synthesized, antother region localized between anino acids 595 and 614 gave a positive reaction with almost 100%IgG-positive serum samples. When it is expressed as recombinant protein,this region also reacted efficiently with HCMV=specific IgM.The two coding regions were recently fused together and were shown to produce a double-epitope fusion protein which can replace the entire p150 molecule in its lgM-binding ability. Another HCMV protein which reacts very well with IgM is ppUL44, the nonstructural DNA-binding protein of 52 kDa. The carboxy-terminal part of th molecule was chosen because it does not contain relevant amino acid sequences cross-reacting with the homologous protein of other members of the Herpesviridae family. The carboxy-terminal half of this protein was expressed and tested with human sera alone and in combination with the double-ppUL32 epitope fusion protein. Besides ppUL32 and ppUL44, two other HCMV proteins were chosen:the major matrix protein ppUL83 and the assembly protein(ppUL80a). The first is known to induce a strong IgM response, and antibodies reacting exclusively to this protein were described during primary infection. The second protein was included in the study because in HCMV-seropositive transplant recipients undergoing viral reactivation, IgM to this protein is very often the first marker to be detected. Use the three proteins together to detect the serums which we have already known the positive or negative of HCMV IgM, the result has fine positive correlation with the result of CMV grade2 antigen,which demonstrate that the chosen proteins contains the antigenic determinants that can react sensitively and specifically with the HCMV IgM. Use the three proteins together according to the optimum to check 100 random sera, this result compared with the results of commercial kits from internal and abroad having excellent efficiency, didn't show significant difference.
引文
[1] 孙冠，周涛，刘洪峰．孕妇巨细胞病毒感染与优生的关联中华中西医杂志，2003年11月第4卷第21期
[2] Hanshaw JB.Cytomegalovirus infection.Pediatr Rev,1995,16:43-48
[3] Peckham CS.Cytomegalovirus infection:congenital and neonatal disease. Scand J Infect Dis Suppl,1991,80:82-87
[4] Drew WL, Sweet ES,Miner RC,et al.Multiple infections by cytomegalovirus in patients with acquired immunodeficiencysyndrome:documentation by Southen blot hybridization. J Infect Dis,1984,150:952-953
[5] Spector SA, Hirata KK, Newman TR.Ideitification of multiple cytomegalovirus strains in homosexual men with acquired immunodeficiency syndrome. J Infect Dis,1984,150:953-956
[6] Chous SW.Reantivation and recombination of multiple cytomegalovirus strains from individual organ donors. J Infect Dis,1989,160:11-16
[7] M.P.Landini,T.Lazzarotto,G.T.Maine, et al Recombinant mono- and polyantigens to detect cytomegalovirus-specific immunoglobulin M in human sera by enzyme immunoassay.J. Ciin. Microbiol., 1995. Oct:2535-2542
[8] Ho,m. Cytomegalovirus.Biology and infection,2nd ed.Plenum medical press,New York;1991
[9] 金奇．医学分子病毒学．北京：科学出版社，2001．762-768
[10] Chee MS,Bankier AT, Beck S,et al.Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169.Curr Top Microbiol Immunol,1990,154:125-169
[11] 李应光，李静，李荣杰．人巨细胞病毒的流行病学与预防研究进展．《国外医学》流行病学传染病学分册．1995，22(2)：71-73
[12] G. T. Maine,R.Stricker, M.Schuler, et al.Development and clinical evaluation of a recombinant-antigen-based cytomegalovirus immunoglobulin M automated immunoassay using the Abbott AxSYM analyzer.J.Clin Microbil., 2000. Apr:1476-1481
[13] M.P.Landini,T.Lazzarotto,G.T.Maine,et al Recombinant mono- and polyantigens to detect cytomegalovirus-specific immunoglobulin M in human sera by enzyme immunoassay.J. Clin. Microbiol., 1995. Oct:2535-2542
[14] 郭大东，高雪芹，朱波等．人巨细胞病毒感染的检测方法．山东医药，2005，45(20)：66-67
[15] Gaytant M A,Steegers E A,Semmekrot B A et al. Congenital cytomegalovirus infection:review of the epidemiology and outcome[J] Obstet Gynecol surv 2002,57(4):245-256
[16] Beockho M W, Leiserring S R,Riddell R A et al.Late cytomegalovirus disease and mortality in allogeneic hematopoietic stem cell transplant recipients:importance of viral and T cell immunity[J].Blood,2003,101:407-414
[17] Bale J F, Miner L, Petheram S Jet al.Congenital cytomegalovirus infection[J] Curr treat options neurol,2002,4(3):225-230
[18] M ichaelis M,Kotchektov R,Vogel Ju,et al.Cytomegalovirus infection blocks apoptosis in cancer cells[J].Celi Mol Life Sci,2004,61 (11): 1307-1316
[19] Distefano A L,A Lonso A,M arein F, et al.Human cytomegalovirus :detection of congenital and perinatal infection in Argentina [J]BMC Pediatr.2004,4(1): 11
[20] M eyer_koening U,W eidm ann M,Kirste G, et al.Cytomegalovirus infection in organ-transplant recipients:diagnostic value of pp65 antigen test,qualitative polymerase chain reaction(PCR)and quantitative Taqman PCR[J]. Transplantation, 2004, 77(11): 1692-1698
[21] Shen YH,Utama B,Wang J,et al Human cytomegalovirus causes endothelial injury through telangiectasia mutant and p53 damage signaling pathways[J] Circ Res,2004,94(10):22
[22]Reinhardt B,Minisini T,Mertens T.Opinion article:Cytomegalovirus is a risk factor in atherogenisis [J]Herpes,2002,9(1):21-23
[23]Altannavch T S,Roubalova K,Broz J,et al.Serologicalmarkers of Chlamydia pneumoniae, cytomegalovirus and helicobactor pylori infection in diabetic and non-diabetic patients with unstable angina pectoris[J] Cent Eur J Public Health,2003,11(2):102-106
[23]Astrid E.Greijer,Jos M.GVan DE Crommert,Servi J.C.Stevens,et al Molecular fine-specificity of anitibody responses to human cytomegalovirus and design of novel synthetic-peptide-baseds serodiagnosis assays[J] J Clin Microbiol, 1999, jan:179-188
[24]The TH,Van den Berg AP,Harmsen Mc,et al.The cytomegalovirus antigenemia assay:a plea for standardization[J].Scand J Infect Dis Suppl, 1995,99:25-29
[25]Ho SKN,Lo CY,Cheng IKP,et al.Rapid cytomegalovirus pp65 antigenemia assay by direct lyssis and immunofluoresence staining[J].J Clin Microbiol, 1998,36:638-640
[26]Imbert -Marcille BM.Robillard N,Poirier AS,et al.Development of a method for direct quanfication of cytomegalovirus antigenemia by flow cytometry[J]. J Clin Microbiol,1997,35:2665-2669
[27]Gleaves CA,Smits TF,Shuster EA,et al.Comparison of standard tube and shell vial culture techniques for the detection of cytomegalovirus in clinical specimen[J]. J Clin Microbiol,1985,21:217-221
[28] 王德智．巨细胞病毒感染与妊娠．中国实用妇科与产科杂志,1995,11(3)：132．
[29]Boeckh M,Boivin G.Quantitation of cytomegalovirus:methodologic aspects and clinical applications[J].Clin Microbiol Rev,1998,11:533-554
[30] Revello,M.G,E.Percivalle,GGerna.Immunoglobulin M to the membrane of the uninfected fibroblasts in primary human cytomegalovirus infections[J]. Microbiology, 1986.9:127-138
[31]Severi B.,M.P.Landini,E.Govoni.Human cytomegalovirus morphogenesis:an ultrastructural study of the late cytoplasmic phases[J].Arch Virol,1988.98:51-64
[32]Biovin G,Handfield J,Toma E,et al.Evaluation of the Amplicor cytomegalovirus test with specimen from human immunodeficiency virus-infected subjects[J]. J Clin Microbiol,1998,36:2905-2912
[33]Pellegrin I,Garrigue I,Binquet C,et al.Evaluation of a new quantative assays for diagnosis and monitoring of cytomegalovirus disease in human immunodeficiency viruspositive patients[J]. J Clin Microbiol,1999,37:3124-3132
[34]Robert TC,Buller RS,Gaudreault-Keener M,et al.Effects of storage temperature and time on qualitative and quantitative detection of cytomegalovirus in blood specimens by shell vial culture and PCR[J]. J Clin Microbiol,1997,35:2224-2228
[35]Caliendo AM,St George K,Kao SY,et al.Comparison of quantative cytomegalovirus PCR in plasma and CMV antigeneima assay.clinical utility ot the prototype Amplicor CMV monitor test in transplant recipients[J].Clin Microbiol,2000,38:2122-2127
[36]Tanaka N,Kimura H,Iida K,et al.Quantitative analysis of cytomegalovirus load using a real-time PCR assay[J]. Med Virol,2000,60:455-462
[37]Blok MG,Goosens VJ,Vanherle SJV,et al.Diagnostic value of monitoring human cytomegalovirus late pp67 mRNA expression in renal-allograft recipeients by nucleic acid sequence-based amplification[J]. Clin Microbiol,1998,36:1341-1346
[38]Gerna G,Baldanti F,Lilleri D,et al.Human cyotmegalovirus immediate-early mRNA detection by nucleic acid sequence-based amplification as a new parameter or preemptive therapy in bone marrow transplant recipients [J]. Clin Microbiol,2000,38:1845-1853
[39]M.P.Landini,T.Lazzarotto,G.T.Maine,et al Recombinant mono- and polyantigens to detect cytomegalovirus-specific immunoglobulin M in human sera by enzyme immunoassay[J]. Clin Microbiol, 1995. Oct:2535-2542
[40]T.Lazzarotto,A.Ripalti,GBergamini et al.Development of a new cytomegalovirus(CMV)immunoblot for detection of CMV-specific IgM[J]. Clin Microbiol, 1998. Nov:3337-3341
[41]M.P.Landini,E.Rossier,H.Schmitz,Antibodies to human cytomegalovirus structural polypeptides during primary infection[J]. Irol Methods, 1988.22:309-317
[42]Bernard Weber,Ei Hadji M.Bargane Fall,Annemarie Berger,et al Screening of blood donors for human cytomegalovirus (HCMV)IgG antibody with an enzyme immunoassay using recombinant antigens [J]. Clin virol, 1999.14:173-181
[43]M.P.Landini,T. Lazarotto ,P.F.Ertl.Humoral immune response to human cytomegalovirus DNA polymerase[J].Clin Microbiol,1993.31:724-726
[44]M.P.Landini,T. Lazarotto ,A.Ripalti.Antibody response to recombinant lambda gt11 fusion proteins in cytomegalovirus infection[J], Clin Microbiol, 1989.27:2324-2327
[45]H.Meyer,A.T.Bankier,M.P.landini.Identification and procaryoticexpression of the gene coding for the highly immunogenic 28-kilodalton structural phosphosprotein(pp28)of human cytomegalovirus[J]. Clin Microbiol, 1988.62:2243 -2250
[46]B.Plachter,L.Wieczorek,B.C.Scholl,Detection of cytomegalovirus antivodies by an eyzymelinked immunosorbent assay using recombinant polypeptides of the large phosphorylated tegument protein ppl50[J]. Clin Microbiol,1992.30:201-206
[47]Astrid E.Greijer,Jos M.GVan DE Crommert,Servi J.C.Stevens,et al Molecular fine-specificity of anitibody responses to human cytomegalovirus and design of novel synthetic-peptide-baseds serodiagnosis assays[J] Clin Microbiol, 1999. jan:179-188
[48]M.P.Landini,T. Lazarotto ,A.Ripalti.Antibody response to recombinant lambda gt11 fusion proteins in cytomegalovirus infection[J]. Clin Microbiol, 1989.27:2324-2327
[49]Jahn,G.,T.Kouzarides,M.Mach,et al.Map position and nucleotide sequence of the gene for the large structural phosphoprotein of human cytomegalovirus[J]. Virol,1987.61:1358-1367
[50]Jahn,G,B.C.Scholl,B.Traupe,et al.The two major phosphoproteins(pp65 and pp150) of human cytomegalovirus and their antigenic properities[J].Gen Virol, 1987.68:1327-1337
[51]M.P.Landini,T.Lazzarotto,G.T.Maine,et al Recombinant mono- and polyantigens to detect cytomegalovirus-specific immunoglobulin M in human sera by enzyme immunoassay[J]. Clin Microbiol, 1995. Oct:2535-2542
[52]M.P.Landini,A.Ripalti,K.Sra,et al.Human immune response to cytomegalovirus structural polypeptides studied by immunoblotting[J]. Med Virol, 1991,29:1868-1872
[53]A.Ripalti, M.P.Landini,E.S.Mocarski,et al.Identification and preliminary use of recombinant labda gt11 fusion proteins in cytomegalovirus diagnosis[J].Gen Virol, 1989.70:1247-1251
[54]Plachter B,Wieczorek L,Scholl BC,et al.Detection of cytomegalovirus antibodies by an enzyme-linked immunosorbent assay using recombinant polypeptides of the large phosphorylated tegument protein ppl50[J]. Clin Microbiol,1992,30:201-206
[55]Ripalti,A.Ruan,M.C.Boccuni,et al.Construction of a polypitpe fusion antigens of human cytomegalovirus ppUL32:reactivity with human antibodies[J]. Clin Microbiol, 1994,32:358-363
[56]Ripalti,A., M.C.Boccuni,F.Campanini,et al.Construction of a polyepitope fusion antigen of human cytomeglovirus ppUL32 and detection of specific antibodies by ELISA[J].Microbiologica,1994,18:l-12
[57]Isao Takahashi,Sayoko Sugiura,Hirotoshi Ohta,et al Epitope analysis of antibodies in Japanese to human cytomegalovirus phosphoprotein 150 with synthetic peptides[J]. Biosci Biotechnol Biochem,2002,66(11):2402-2405
[58] M. P. Landini, T. Lazzarotto, G. T. Maine, et al Recombinant mono- and polyantigens to detect cytomegalovirus-specific immunoglobulin M in human sera by enzyme immunoassay[J]. Clin Microbiol., 1995, Oct: 2535-2542
[59] T. Lazzarotto, G. T. Maine, P. Dal Monte, et al A novel western blot test containing both viral and recombinant proteins for anticytomegalovirus immunoglobulin M Detection [J]. Clin Microbiol, 1997, Feb: 393-397
[60] M. Grazia Revello, Elena Percivalle, Marco Zannino, et al Development and evaluation of a capture eLISA for IgM antibody to the human cytomegalovirus major DNA binding protein [J]. Virol Methods, 1991, 35: 315-329
[61] Ripalti A., P. Dal Monte, M. C. boccuni et al. Prokaryotic expression of a large fragment of the most antigenic cytomegalovirus DNA-binding proteins (ppUL44)and its reactivity with human antibodies[J]. Virol Method, 1994, 46: 39-50
[62] Ripalti, A., M. C. Boccuni, F. Campanini, et al. Construction of a polyepitope fusion antigen of human cytomeglovirus ppUL32 and detection of specific antibodies by ELISA. Microbiologica, 1994. 18: 1-12
[63] M. P. Landini, M. X. Guan, G. Jahn, et al. Large-scale screening of human sera with cytomegalovirus recombinant antigens[J]. Clin Microbiol, 1990, 28: 1375-1379
[64] G. T. Maine, T. Lazzarotto, L. E. Chovan, et al The DNA-binding protein pUL57 of human cytomegalovirus: comparison of specific immunoglobulin M(IgM) reactivity to other major target antigens[J]. Clin Diagn La Immunol, 1996, May: 358-360
[65] 杭建峰，吴英松，李明。时间分辨荧光免疫分析的研究进展及其应用[J]．热带医学杂志，2004：4(3)：340-343
[66] Campbell TN, Choy FY. Expression of the green fluorescent protein variants in citrate-buffered media in Pichia pastoris[J]. Analytical Biochemistry, 2002; 311(2): 193-195
[67] Spaete RR, Gehra R, Landini MP. Human cytomegalovirus structural proteins[J]. J Gen Virol, 1994; 75: 3287-3308
[68] 周铁群，沉月雷，邱平到等．人巨细胞病毒大外膜磷蛋白pp150羧基末端的高效表达及初步应用[J]．微生物学免疫学进展，1999；27(2)：28-31
[69] Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science, 1990, 247(4949pt1): 1465-1468
[70] Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein[J]. Science, 1993, 159(5102): 1745-1749
[72] Maine, G. T., T. Lazzarotto, L. E. Chovan, et al. The DNA-binding protein pUL57 of human cytomegalovirus: comparison of specific immunoglobulin M(IgM)reactivity with IgM reactivity to other major target antigens[J]. Clin Diagn Lab Immunol, 1996. 3: 358-360
[73] 汪家政 《蛋白质技术手册》中国中医药出版社 2002-4 第一版
[74] J．萨姆布鲁克，E．F．弗里奇，T．曼尼阿蒂斯，《分子克隆》(第二版)，科学出版社，1994-8
[75] 颜子颖 精编现代分子生物学实验指南 科学出版社 2001-3-12
[76] 宁云山，李妍，王小宁．包涵体蛋白质的复性研究进展 生物技术通讯 200112(3) 237-240
[77] 纪剑飞，张成刚．包涵体重组蛋白的纯化及复性 沈阳药科大学学报 1998年04期 303-307
[78] 黄泓，张伟．包涵体的体外复性研究进展 生命的化学 2003年05期398-400
[79] Li LH, Schwarz E, Rudolph R. Advances in refolding of proteins produced in E. coli. [J]. Curr Opin Biotechnol 1998, 9(5): 497-501
[80] Werner M H, Clore G M, Refolding proteins by gel filtration chromatography[J]. FEBS Lett, 1994, 345(2)
[81] 冯小黎．重组包涵体蛋白质的折叠复性 生物化学与生物物理进展 2001：28(4)
[82] 王颖 董晓燕．蛋白质复性技术研究进展 生物工程进展 2002，V22，NO．2
[83] [美]D．R．马歇克等著 朱厚础 译．蛋白质纯化与鉴定实验指南 科学出版社2002年5月第一版
[84] 范代娣 沈立新 米钰．重组蛋白分离与分析 化学工业出版社 2004年9月第一版
[85] 黄飚，肖龙华，朱利国等．HBeAg时间分辨荧光免疫分析法的建立[J]．标记免疫分析与临床，2002，9(2)：96-8
[86] 武学成，何林，周克林．时间分辨荧光免疫分析技术及临床应用[J]．医学综述，2006．12(7)：434-436
[87] Uehar M, Arai Y, Watarbe's, et al. Comparison of plasma and urinary phytoestrogens in Japanese and Finnish women by time-resolved fluoroimmunoassay[J]. Biofactors, 2000; 12(1-4): 217-225
[88] 赵启仁．时间分辨荧光免疫分析及其应用前景[J]．国外医学．放射医学核医学分册，1992，16(4)：182-188
[90] 沈健，林德球，徐杰．时间分辨荧光免疫分析技术研究现状及进展[J]．生命科学，2004，16(1)：55-59
[91] 周伟玲，赵启仁．时间分辨荧光分析技术的研究进展及应用[J]．国际放射医学核医学杂志，2006，30(2)：103-106
[1] 张晨光，陆志檬 巨细胞病毒感染的实验室诊断和治疗现状 国外医学流行病 学传染病学分册 1997; 24 (1) 6-11
[2]Gaytant M A,Steegers E A,Semmekrot B A et al. Congenital cytomegalovirus infection:review of the epidemiology and outcome[J]. Obstet Gynecol surv 2002,57(4):245-256
[3]Beockho M W,Leiserring S R,Riddell R A et al.Late cytomegalovirus disease and mortality in allogeneic hematopoietic stem cell transplant recipients.importance of viral and T cell immunity[J].Blood,2003,101:407-414
[4]Bale J F,Miner L,Petheram S J et al.Congenital cytomegalovirus infection[J] Curr treat options neurol,2002,4(3):225-230
[5]Shen YH,Utama B,Wang J,et al Human cytomegalovirus causes endothelial injury through telangiectasia mutant and p53 damage signaling pathways[J] Circ Res,2004,94(10):22
[6]Reinhardt B,Minisini T,Mertens T.Opinion article:Cytomegalovirus is a risk factor in atherogenisis [J]Herpes,2002,9(1):21-23
[7]Altannavch T S,Roubalova K,Broz J,et al.Serologicalmarkers of Chlamydia pneumoniae, cytomegalovirus and helicobactor pylori infection in diabetic and non-diabetic patients with unstable angina pectoris[J] Cent Eur J Public Health,2003,11(2):102-106
[8]M ichaelis M,Kotchektov R,Vogel Ju,et al.Cytomegalovirus infection blocks apoptosis in cancer cells[J].Cell Mol Life Sci,2004,61(11):1307-1316
[9]Distefano A L,A Lonso A,M arein F,et al.Human cytomegalovirus :detection of congenital and perinatal infection in Argentina [J]BMC Pediatr.2004,4(1):11
[10]M eyerkoening U,W eidm ann M,Kirste G,et al.Cytomegalovirus infection in organ-transplant recipients:diagnostic value of pp65 antigen test,qualitative polymerase chain reaction(PCR)and quantitative Taqman PCR[J].Transplantation , 2004,77(11):1692-1698
[11] Beockho M W, Leiserring S R, Riddell R A et al. Late cytomegalovirus disease and mortality in allogeneic hematopoietic stem cell transplant recipients: importance of viral and T cell immunity[J]. Blood, 2003, 101: 407-414
[12] Bale J F, Miner L, Petheram S Jet al. Congenital cytomegalovirus infection[J] Curr treat options neurol, 2002, 4(3): 225-230
[13] 陈敦金，赵杨，闻良珍．人巨细胞病毒感染对宿主细胞周期的影响．热带医学杂志，2003，3(4)：481-483．
[14] Maine GT, Stricker R, Schuler M, et al. Development and clinical evaluation of a recombinant-antigen-based cytomegalovirus immunoglobulin M automated immunoassay using the Abbott AxSYM analyzer[J]. J Clin Microbil, 2000, 38(4): 1476-1481.
[15] Landini MP, Lazzarotto T, Maine GT, et al. Recombinant mono- and polyantigens to detect cytomegalovirus-specific immunoglobulin M in human sera by enzyme immunoassay[J]. J Clin. Microbiol, 1995, 33(10): 2535-2542.
[16] Astrid EG, Jos MG, Servi JC, et al. Molecular fine-specificity of anitibody responses to human cytomegalovirus and design of novel synthetic-peptide-based serodiagnosis assays[J]. J Clin. Microbiol, 1999, 37(1): 179-188.
[17] Lazzarotto T, Ripalti A, Bergamini G, et al. Development of a new cytomegalovirus(CMV) Immunoblot for detection of CMV-specific IgM[J]. J Clin. Microbiol, 1998, 36(11): 3337-3341.
[18] 方毅，司炳银，张雨，等．HCMV gp52基因的克隆与表达式．军事医学科学院院刊，2003，27(5)：363-366．
[19] 邱红玉，孙永玉．HCMV pp65的基础及应用研究．国外医学病毒学分册，2001，8(5)：141-144
[20] 李国才，严华，季明春，等．人巨细胸病毒pp150抗原区的原核表达及初步应用．病毒学报，2004，20(2)：169-171．
[21] Lazzarotto T, Maine GT, Dal MP, et al. A novel western blot test containing both viral and recombinant proteins for anticytomegalovirus immunoglobulin M Detection[J].J Clin Microbiol, 1997, 35(2): 393-397.
[2] Hanshaw JB.Cytomegalovirus infection.Pediatr Rev,1995,16:43-48
[3] Peckham CS.Cytomegalovirus infection:congenital and neonatal disease. Scand J Infect Dis Suppl,1991,80:82-87
[4] Drew WL, Sweet ES,Miner RC,et al.Multiple infections by cytomegalovirus in patients with acquired immunodeficiencysyndrome:documentation by Southen blot hybridization. J Infect Dis,1984,150:952-953
[5] Spector SA, Hirata KK, Newman TR.Ideitification of multiple cytomegalovirus strains in homosexual men with acquired immunodeficiency syndrome. J Infect Dis,1984,150:953-956
[6] Chous SW.Reantivation and recombination of multiple cytomegalovirus strains from individual organ donors. J Infect Dis,1989,160:11-16
[7] M.P.Landini,T.Lazzarotto,G.T.Maine, et al Recombinant mono- and polyantigens to detect cytomegalovirus-specific immunoglobulin M in human sera by enzyme immunoassay.J. Ciin. Microbiol., 1995. Oct:2535-2542
[8] Ho,m. Cytomegalovirus.Biology and infection,2nd ed.Plenum medical press,New York;1991
[9] 金奇．医学分子病毒学．北京：科学出版社，2001．762-768
[10] Chee MS,Bankier AT, Beck S,et al.Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169.Curr Top Microbiol Immunol,1990,154:125-169
[11] 李应光，李静，李荣杰．人巨细胞病毒的流行病学与预防研究进展．《国外医学》流行病学传染病学分册．1995，22(2)：71-73
[12] G. T. Maine,R.Stricker, M.Schuler, et al.Development and clinical evaluation of a recombinant-antigen-based cytomegalovirus immunoglobulin M automated immunoassay using the Abbott AxSYM analyzer.J.Clin Microbil., 2000. Apr:1476-1481
[13] M.P.Landini,T.Lazzarotto,G.T.Maine,et al Recombinant mono- and polyantigens to detect cytomegalovirus-specific immunoglobulin M in human sera by enzyme immunoassay.J. Clin. Microbiol., 1995. Oct:2535-2542
[14] 郭大东，高雪芹，朱波等．人巨细胞病毒感染的检测方法．山东医药，2005，45(20)：66-67
[15] Gaytant M A,Steegers E A,Semmekrot B A et al. Congenital cytomegalovirus infection:review of the epidemiology and outcome[J] Obstet Gynecol surv 2002,57(4):245-256
[16] Beockho M W, Leiserring S R,Riddell R A et al.Late cytomegalovirus disease and mortality in allogeneic hematopoietic stem cell transplant recipients:importance of viral and T cell immunity[J].Blood,2003,101:407-414
[17] Bale J F, Miner L, Petheram S Jet al.Congenital cytomegalovirus infection[J] Curr treat options neurol,2002,4(3):225-230
[18] M ichaelis M,Kotchektov R,Vogel Ju,et al.Cytomegalovirus infection blocks apoptosis in cancer cells[J].Celi Mol Life Sci,2004,61 (11): 1307-1316
[19] Distefano A L,A Lonso A,M arein F, et al.Human cytomegalovirus :detection of congenital and perinatal infection in Argentina [J]BMC Pediatr.2004,4(1): 11
[20] M eyer_koening U,W eidm ann M,Kirste G, et al.Cytomegalovirus infection in organ-transplant recipients:diagnostic value of pp65 antigen test,qualitative polymerase chain reaction(PCR)and quantitative Taqman PCR[J]. Transplantation, 2004, 77(11): 1692-1698
[21] Shen YH,Utama B,Wang J,et al Human cytomegalovirus causes endothelial injury through telangiectasia mutant and p53 damage signaling pathways[J] Circ Res,2004,94(10):22
[22]Reinhardt B,Minisini T,Mertens T.Opinion article:Cytomegalovirus is a risk factor in atherogenisis [J]Herpes,2002,9(1):21-23
[23]Altannavch T S,Roubalova K,Broz J,et al.Serologicalmarkers of Chlamydia pneumoniae, cytomegalovirus and helicobactor pylori infection in diabetic and non-diabetic patients with unstable angina pectoris[J] Cent Eur J Public Health,2003,11(2):102-106
[23]Astrid E.Greijer,Jos M.GVan DE Crommert,Servi J.C.Stevens,et al Molecular fine-specificity of anitibody responses to human cytomegalovirus and design of novel synthetic-peptide-baseds serodiagnosis assays[J] J Clin Microbiol, 1999, jan:179-188
[24]The TH,Van den Berg AP,Harmsen Mc,et al.The cytomegalovirus antigenemia assay:a plea for standardization[J].Scand J Infect Dis Suppl, 1995,99:25-29
[25]Ho SKN,Lo CY,Cheng IKP,et al.Rapid cytomegalovirus pp65 antigenemia assay by direct lyssis and immunofluoresence staining[J].J Clin Microbiol, 1998,36:638-640
[26]Imbert -Marcille BM.Robillard N,Poirier AS,et al.Development of a method for direct quanfication of cytomegalovirus antigenemia by flow cytometry[J]. J Clin Microbiol,1997,35:2665-2669
[27]Gleaves CA,Smits TF,Shuster EA,et al.Comparison of standard tube and shell vial culture techniques for the detection of cytomegalovirus in clinical specimen[J]. J Clin Microbiol,1985,21:217-221
[28] 王德智．巨细胞病毒感染与妊娠．中国实用妇科与产科杂志,1995,11(3)：132．
[29]Boeckh M,Boivin G.Quantitation of cytomegalovirus:methodologic aspects and clinical applications[J].Clin Microbiol Rev,1998,11:533-554
[30] Revello,M.G,E.Percivalle,GGerna.Immunoglobulin M to the membrane of the uninfected fibroblasts in primary human cytomegalovirus infections[J]. Microbiology, 1986.9:127-138
[31]Severi B.,M.P.Landini,E.Govoni.Human cytomegalovirus morphogenesis:an ultrastructural study of the late cytoplasmic phases[J].Arch Virol,1988.98:51-64
[32]Biovin G,Handfield J,Toma E,et al.Evaluation of the Amplicor cytomegalovirus test with specimen from human immunodeficiency virus-infected subjects[J]. J Clin Microbiol,1998,36:2905-2912
[33]Pellegrin I,Garrigue I,Binquet C,et al.Evaluation of a new quantative assays for diagnosis and monitoring of cytomegalovirus disease in human immunodeficiency viruspositive patients[J]. J Clin Microbiol,1999,37:3124-3132
[34]Robert TC,Buller RS,Gaudreault-Keener M,et al.Effects of storage temperature and time on qualitative and quantitative detection of cytomegalovirus in blood specimens by shell vial culture and PCR[J]. J Clin Microbiol,1997,35:2224-2228
[35]Caliendo AM,St George K,Kao SY,et al.Comparison of quantative cytomegalovirus PCR in plasma and CMV antigeneima assay.clinical utility ot the prototype Amplicor CMV monitor test in transplant recipients[J].Clin Microbiol,2000,38:2122-2127
[36]Tanaka N,Kimura H,Iida K,et al.Quantitative analysis of cytomegalovirus load using a real-time PCR assay[J]. Med Virol,2000,60:455-462
[37]Blok MG,Goosens VJ,Vanherle SJV,et al.Diagnostic value of monitoring human cytomegalovirus late pp67 mRNA expression in renal-allograft recipeients by nucleic acid sequence-based amplification[J]. Clin Microbiol,1998,36:1341-1346
[38]Gerna G,Baldanti F,Lilleri D,et al.Human cyotmegalovirus immediate-early mRNA detection by nucleic acid sequence-based amplification as a new parameter or preemptive therapy in bone marrow transplant recipients [J]. Clin Microbiol,2000,38:1845-1853
[39]M.P.Landini,T.Lazzarotto,G.T.Maine,et al Recombinant mono- and polyantigens to detect cytomegalovirus-specific immunoglobulin M in human sera by enzyme immunoassay[J]. Clin Microbiol, 1995. Oct:2535-2542
[40]T.Lazzarotto,A.Ripalti,GBergamini et al.Development of a new cytomegalovirus(CMV)immunoblot for detection of CMV-specific IgM[J]. Clin Microbiol, 1998. Nov:3337-3341
[41]M.P.Landini,E.Rossier,H.Schmitz,Antibodies to human cytomegalovirus structural polypeptides during primary infection[J]. Irol Methods, 1988.22:309-317
[42]Bernard Weber,Ei Hadji M.Bargane Fall,Annemarie Berger,et al Screening of blood donors for human cytomegalovirus (HCMV)IgG antibody with an enzyme immunoassay using recombinant antigens [J]. Clin virol, 1999.14:173-181
[43]M.P.Landini,T. Lazarotto ,P.F.Ertl.Humoral immune response to human cytomegalovirus DNA polymerase[J].Clin Microbiol,1993.31:724-726
[44]M.P.Landini,T. Lazarotto ,A.Ripalti.Antibody response to recombinant lambda gt11 fusion proteins in cytomegalovirus infection[J], Clin Microbiol, 1989.27:2324-2327
[45]H.Meyer,A.T.Bankier,M.P.landini.Identification and procaryoticexpression of the gene coding for the highly immunogenic 28-kilodalton structural phosphosprotein(pp28)of human cytomegalovirus[J]. Clin Microbiol, 1988.62:2243 -2250
[46]B.Plachter,L.Wieczorek,B.C.Scholl,Detection of cytomegalovirus antivodies by an eyzymelinked immunosorbent assay using recombinant polypeptides of the large phosphorylated tegument protein ppl50[J]. Clin Microbiol,1992.30:201-206
[47]Astrid E.Greijer,Jos M.GVan DE Crommert,Servi J.C.Stevens,et al Molecular fine-specificity of anitibody responses to human cytomegalovirus and design of novel synthetic-peptide-baseds serodiagnosis assays[J] Clin Microbiol, 1999. jan:179-188
[48]M.P.Landini,T. Lazarotto ,A.Ripalti.Antibody response to recombinant lambda gt11 fusion proteins in cytomegalovirus infection[J]. Clin Microbiol, 1989.27:2324-2327
[49]Jahn,G.,T.Kouzarides,M.Mach,et al.Map position and nucleotide sequence of the gene for the large structural phosphoprotein of human cytomegalovirus[J]. Virol,1987.61:1358-1367
[50]Jahn,G,B.C.Scholl,B.Traupe,et al.The two major phosphoproteins(pp65 and pp150) of human cytomegalovirus and their antigenic properities[J].Gen Virol, 1987.68:1327-1337
[51]M.P.Landini,T.Lazzarotto,G.T.Maine,et al Recombinant mono- and polyantigens to detect cytomegalovirus-specific immunoglobulin M in human sera by enzyme immunoassay[J]. Clin Microbiol, 1995. Oct:2535-2542
[52]M.P.Landini,A.Ripalti,K.Sra,et al.Human immune response to cytomegalovirus structural polypeptides studied by immunoblotting[J]. Med Virol, 1991,29:1868-1872
[53]A.Ripalti, M.P.Landini,E.S.Mocarski,et al.Identification and preliminary use of recombinant labda gt11 fusion proteins in cytomegalovirus diagnosis[J].Gen Virol, 1989.70:1247-1251
[54]Plachter B,Wieczorek L,Scholl BC,et al.Detection of cytomegalovirus antibodies by an enzyme-linked immunosorbent assay using recombinant polypeptides of the large phosphorylated tegument protein ppl50[J]. Clin Microbiol,1992,30:201-206
[55]Ripalti,A.Ruan,M.C.Boccuni,et al.Construction of a polypitpe fusion antigens of human cytomegalovirus ppUL32:reactivity with human antibodies[J]. Clin Microbiol, 1994,32:358-363
[56]Ripalti,A., M.C.Boccuni,F.Campanini,et al.Construction of a polyepitope fusion antigen of human cytomeglovirus ppUL32 and detection of specific antibodies by ELISA[J].Microbiologica,1994,18:l-12
[57]Isao Takahashi,Sayoko Sugiura,Hirotoshi Ohta,et al Epitope analysis of antibodies in Japanese to human cytomegalovirus phosphoprotein 150 with synthetic peptides[J]. Biosci Biotechnol Biochem,2002,66(11):2402-2405
[58] M. P. Landini, T. Lazzarotto, G. T. Maine, et al Recombinant mono- and polyantigens to detect cytomegalovirus-specific immunoglobulin M in human sera by enzyme immunoassay[J]. Clin Microbiol., 1995, Oct: 2535-2542
[59] T. Lazzarotto, G. T. Maine, P. Dal Monte, et al A novel western blot test containing both viral and recombinant proteins for anticytomegalovirus immunoglobulin M Detection [J]. Clin Microbiol, 1997, Feb: 393-397
[60] M. Grazia Revello, Elena Percivalle, Marco Zannino, et al Development and evaluation of a capture eLISA for IgM antibody to the human cytomegalovirus major DNA binding protein [J]. Virol Methods, 1991, 35: 315-329
[61] Ripalti A., P. Dal Monte, M. C. boccuni et al. Prokaryotic expression of a large fragment of the most antigenic cytomegalovirus DNA-binding proteins (ppUL44)and its reactivity with human antibodies[J]. Virol Method, 1994, 46: 39-50
[62] Ripalti, A., M. C. Boccuni, F. Campanini, et al. Construction of a polyepitope fusion antigen of human cytomeglovirus ppUL32 and detection of specific antibodies by ELISA. Microbiologica, 1994. 18: 1-12
[63] M. P. Landini, M. X. Guan, G. Jahn, et al. Large-scale screening of human sera with cytomegalovirus recombinant antigens[J]. Clin Microbiol, 1990, 28: 1375-1379
[64] G. T. Maine, T. Lazzarotto, L. E. Chovan, et al The DNA-binding protein pUL57 of human cytomegalovirus: comparison of specific immunoglobulin M(IgM) reactivity to other major target antigens[J]. Clin Diagn La Immunol, 1996, May: 358-360
[65] 杭建峰，吴英松，李明。时间分辨荧光免疫分析的研究进展及其应用[J]．热带医学杂志，2004：4(3)：340-343
[66] Campbell TN, Choy FY. Expression of the green fluorescent protein variants in citrate-buffered media in Pichia pastoris[J]. Analytical Biochemistry, 2002; 311(2): 193-195
[67] Spaete RR, Gehra R, Landini MP. Human cytomegalovirus structural proteins[J]. J Gen Virol, 1994; 75: 3287-3308
[68] 周铁群，沉月雷，邱平到等．人巨细胞病毒大外膜磷蛋白pp150羧基末端的高效表达及初步应用[J]．微生物学免疫学进展，1999；27(2)：28-31
[69] Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science, 1990, 247(4949pt1): 1465-1468
[70] Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein[J]. Science, 1993, 159(5102): 1745-1749
[72] Maine, G. T., T. Lazzarotto, L. E. Chovan, et al. The DNA-binding protein pUL57 of human cytomegalovirus: comparison of specific immunoglobulin M(IgM)reactivity with IgM reactivity to other major target antigens[J]. Clin Diagn Lab Immunol, 1996. 3: 358-360
[73] 汪家政 《蛋白质技术手册》中国中医药出版社 2002-4 第一版
[74] J．萨姆布鲁克，E．F．弗里奇，T．曼尼阿蒂斯，《分子克隆》(第二版)，科学出版社，1994-8
[75] 颜子颖 精编现代分子生物学实验指南 科学出版社 2001-3-12
[76] 宁云山，李妍，王小宁．包涵体蛋白质的复性研究进展 生物技术通讯 200112(3) 237-240
[77] 纪剑飞，张成刚．包涵体重组蛋白的纯化及复性 沈阳药科大学学报 1998年04期 303-307
[78] 黄泓，张伟．包涵体的体外复性研究进展 生命的化学 2003年05期398-400
[79] Li LH, Schwarz E, Rudolph R. Advances in refolding of proteins produced in E. coli. [J]. Curr Opin Biotechnol 1998, 9(5): 497-501
[80] Werner M H, Clore G M, Refolding proteins by gel filtration chromatography[J]. FEBS Lett, 1994, 345(2)
[81] 冯小黎．重组包涵体蛋白质的折叠复性 生物化学与生物物理进展 2001：28(4)
[82] 王颖 董晓燕．蛋白质复性技术研究进展 生物工程进展 2002，V22，NO．2
[83] [美]D．R．马歇克等著 朱厚础 译．蛋白质纯化与鉴定实验指南 科学出版社2002年5月第一版
[84] 范代娣 沈立新 米钰．重组蛋白分离与分析 化学工业出版社 2004年9月第一版
[85] 黄飚，肖龙华，朱利国等．HBeAg时间分辨荧光免疫分析法的建立[J]．标记免疫分析与临床，2002，9(2)：96-8
[86] 武学成，何林，周克林．时间分辨荧光免疫分析技术及临床应用[J]．医学综述，2006．12(7)：434-436
[87] Uehar M, Arai Y, Watarbe's, et al. Comparison of plasma and urinary phytoestrogens in Japanese and Finnish women by time-resolved fluoroimmunoassay[J]. Biofactors, 2000; 12(1-4): 217-225
[88] 赵启仁．时间分辨荧光免疫分析及其应用前景[J]．国外医学．放射医学核医学分册，1992，16(4)：182-188
[90] 沈健，林德球，徐杰．时间分辨荧光免疫分析技术研究现状及进展[J]．生命科学，2004，16(1)：55-59
[91] 周伟玲，赵启仁．时间分辨荧光分析技术的研究进展及应用[J]．国际放射医学核医学杂志，2006，30(2)：103-106
[1] 张晨光，陆志檬 巨细胞病毒感染的实验室诊断和治疗现状 国外医学流行病 学传染病学分册 1997; 24 (1) 6-11
[2]Gaytant M A,Steegers E A,Semmekrot B A et al. Congenital cytomegalovirus infection:review of the epidemiology and outcome[J]. Obstet Gynecol surv 2002,57(4):245-256
[3]Beockho M W,Leiserring S R,Riddell R A et al.Late cytomegalovirus disease and mortality in allogeneic hematopoietic stem cell transplant recipients.importance of viral and T cell immunity[J].Blood,2003,101:407-414
[4]Bale J F,Miner L,Petheram S J et al.Congenital cytomegalovirus infection[J] Curr treat options neurol,2002,4(3):225-230
[5]Shen YH,Utama B,Wang J,et al Human cytomegalovirus causes endothelial injury through telangiectasia mutant and p53 damage signaling pathways[J] Circ Res,2004,94(10):22
[6]Reinhardt B,Minisini T,Mertens T.Opinion article:Cytomegalovirus is a risk factor in atherogenisis [J]Herpes,2002,9(1):21-23
[7]Altannavch T S,Roubalova K,Broz J,et al.Serologicalmarkers of Chlamydia pneumoniae, cytomegalovirus and helicobactor pylori infection in diabetic and non-diabetic patients with unstable angina pectoris[J] Cent Eur J Public Health,2003,11(2):102-106
[8]M ichaelis M,Kotchektov R,Vogel Ju,et al.Cytomegalovirus infection blocks apoptosis in cancer cells[J].Cell Mol Life Sci,2004,61(11):1307-1316
[9]Distefano A L,A Lonso A,M arein F,et al.Human cytomegalovirus :detection of congenital and perinatal infection in Argentina [J]BMC Pediatr.2004,4(1):11
[10]M eyerkoening U,W eidm ann M,Kirste G,et al.Cytomegalovirus infection in organ-transplant recipients:diagnostic value of pp65 antigen test,qualitative polymerase chain reaction(PCR)and quantitative Taqman PCR[J].Transplantation , 2004,77(11):1692-1698
[11] Beockho M W, Leiserring S R, Riddell R A et al. Late cytomegalovirus disease and mortality in allogeneic hematopoietic stem cell transplant recipients: importance of viral and T cell immunity[J]. Blood, 2003, 101: 407-414
[12] Bale J F, Miner L, Petheram S Jet al. Congenital cytomegalovirus infection[J] Curr treat options neurol, 2002, 4(3): 225-230
[13] 陈敦金，赵杨，闻良珍．人巨细胞病毒感染对宿主细胞周期的影响．热带医学杂志，2003，3(4)：481-483．
[14] Maine GT, Stricker R, Schuler M, et al. Development and clinical evaluation of a recombinant-antigen-based cytomegalovirus immunoglobulin M automated immunoassay using the Abbott AxSYM analyzer[J]. J Clin Microbil, 2000, 38(4): 1476-1481.
[15] Landini MP, Lazzarotto T, Maine GT, et al. Recombinant mono- and polyantigens to detect cytomegalovirus-specific immunoglobulin M in human sera by enzyme immunoassay[J]. J Clin. Microbiol, 1995, 33(10): 2535-2542.
[16] Astrid EG, Jos MG, Servi JC, et al. Molecular fine-specificity of anitibody responses to human cytomegalovirus and design of novel synthetic-peptide-based serodiagnosis assays[J]. J Clin. Microbiol, 1999, 37(1): 179-188.
[17] Lazzarotto T, Ripalti A, Bergamini G, et al. Development of a new cytomegalovirus(CMV) Immunoblot for detection of CMV-specific IgM[J]. J Clin. Microbiol, 1998, 36(11): 3337-3341.
[18] 方毅，司炳银，张雨，等．HCMV gp52基因的克隆与表达式．军事医学科学院院刊，2003，27(5)：363-366．
[19] 邱红玉，孙永玉．HCMV pp65的基础及应用研究．国外医学病毒学分册，2001，8(5)：141-144
[20] 李国才，严华，季明春，等．人巨细胸病毒pp150抗原区的原核表达及初步应用．病毒学报，2004，20(2)：169-171．
[21] Lazzarotto T, Maine GT, Dal MP, et al. A novel western blot test containing both viral and recombinant proteins for anticytomegalovirus immunoglobulin M Detection[J].J Clin Microbiol, 1997, 35(2): 393-397.